Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Networks (EGGMIO-RGN) | HRSA 21 110

Opportunity Information: Apply for HRSA 21 110

The Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Networks (EGGMIO-RGN) opportunity is a supplemental funding announcement from the Health Resources and Services Administration (HRSA) within the U.S. Department of Health and Human Services. It sits under the existing Regional Genetics Networks (RGN) program (original program reference HRSA-20-046) and is designed to help current RGN awardees take a closer, more rigorous look at how well their ongoing genetics and genomics activities are working in real-world practice. The central idea is not to launch brand-new services, but to evaluate strategies and activities that the networks are already using to expand access to genetic and genomic services, particularly for individuals and families who are underserved or face barriers to care.

At its core, EGGMIO-RGN is about evaluation: measuring implementation and outcomes to understand what is effective, for whom, and under what conditions. HRSA is looking for focused, well-designed assessments that can generate practical findings, such as what improves uptake of genomic tools in clinical settings, what service delivery models produce better access or health outcomes, and what program approaches can be replicated by others. The expectation is that recipients will study the utility, applicability, and effectiveness of one or more existing RGN program activities, producing results that can guide their own improvements while also contributing lessons to the broader field of genetic and genomic medicine and public health.

HRSA plans to make up to three awards through a cooperative agreement mechanism, meaning the agency typically has substantial involvement in the funded work compared with a standard grant. The opportunity is categorized as discretionary funding within the health activity area (CFDA 93.110). Eligibility is listed broadly as "Others (see text field entitled Additional Information on Eligibility for clarification)," but the announcement makes clear that this is supplemental funding under the RGN program, so the practical target audience is RGN recipients that already hold awards under HRSA-20-046. The funding opportunity number is HRSA 21 110. The notice was created April 22, 2021, with an original closing date of June 7, 2021, and HRSA anticipated three total awards. The award ceiling is listed as 0 in the provided record, which often indicates that the cap may be defined elsewhere in the full notice or handled on a supplemental, case-specific basis.

In terms of what HRSA wants evaluated, the announcement highlights several example topics. One is outreach and engagement strategies aimed at primary care providers and other non-genetics clinicians, including education, training, or clinical resources that help them use genomics appropriately in patient care. Another is perceived clinical utility, meaning whether providers, patients, and families believe that RGN-developed genomic resources or tools are helpful across the full care journey, from diagnosis through treatment planning and long-term management. The opportunity also points to evaluation of nontraditional service modalities, such as telehealth-enabled genetic or genomic services, with attention both to implementation (how the service is delivered, adopted, and sustained) and outcomes (such as access, timeliness, quality, or clinical impact). HRSA is also interested in whether RGN-created resources or strategies can be transferred across regions, including adaptations through multi-RGN collaboration and dissemination of lessons learned to address common unmet needs. Finally, the notice calls out the impact of integrating the latest scientific evidence related to particular genetic or genomic conditions, focusing on whether evidence updates improve the usefulness and effectiveness of the program activity.

Overall, EGGMIO-RGN is best understood as an applied evaluation initiative meant to turn experience from the Regional Genetics Networks into actionable evidence. By funding a small number of rigorous evaluations of established RGN strategies, HRSA aims to identify best practices for implementing genetic and genomic advances in clinical and public health settings, while keeping equity and access for underserved populations at the center of the work.

• The Department of Health and Human Services, Health Resources and Services Administration in the health sector is offering a public funding opportunity titled "Evaluating Genetic and Genomic Medicine Implementation and Outcomes in the Regional Genetics Networks (EGGMIO-RGN)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.110.
• This funding opportunity was created on Apr 22, 2021.
• Applicants must submit their applications by Jun 07, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 3 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for HRSA 21 110

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: